Analysts’ Weekly Ratings Updates for Kura Oncology (KURA)

A number of research firms have changed their ratings and price targets for Kura Oncology (NASDAQ: KURA):

• 6/4/2026 – Kura Oncology had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/4/2026 – Kura Oncology was given a new $24.00 price target by CLSA.
• 6/4/2026 – Kura Oncology was given a new $24.00 price target by Wells Fargo & Company.
• 5/28/2026 – Kura Oncology was given a new $24.00 price target by Oppenheimer Holdings, Inc..
• 5/28/2026 – Kura Oncology was given a new $24.00 price target by Jefferies Financial Group Inc..
• 5/28/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/16/2026 – Kura Oncology was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 4/21/2026 – Kura Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/14/2026 – Kura Oncology is now covered by Lake Street Capital. They set a “buy” rating and a $23.00 price target on the stock.
• 4/14/2026 – Kura Oncology is now covered by Lake Street Capital. They set a “buy” rating and a $23.00 price target on the stock.

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.